The Daily Buyout
$820MStrategic acquisitionHealthcare & Life SciencesCompleted

Jazz Pharmaceuticals completes $820M acquisition of Actio Biosciences

Jazz Pharmaceuticals closed its acquisition of privately held Actio Biosciences for $820 million upfront, adding KCNT1-related epilepsy candidate ABS-1230.

Read the full coverage, free

We only link to sources you can read without a subscription. How we check.

More Healthcare & Life Sciences deals